Hengrui Pharma(600276) 证券之星·2025-03-30 08:10Core Viewpoint - The company plans to distribute a cash dividend of 0.2 yuan per share, with a total cash dividend amounting to approximately 1.5 billion yuan, which is 23.73% of the net profit for the year 2024 [1][2][3]. Profit Distribution Plan - The company achieved a net profit of 6,336,527,014.75 yuan for the year 2024, with a total undistributed profit available for distribution of 29,890,061,126.47 yuan [2]. - The proposed cash dividend distribution is 2 yuan for every 10 shares held, translating to a total cash dividend of 1,275,450,072.80 yuan (including tax) based on the total share capital as of March 11, 2025 [2]. - The total cash dividend amount may be adjusted based on the number of shares held in the company's repurchase account on the record date [2]. Cash Dividend Ratio Explanation - The cash dividend ratio is below 30% due to several factors: high investment and risk in the pharmaceutical industry, the company's transition from generic to innovative drugs requiring significant funding for clinical trials and R&D, and ongoing expansion projects in Guangdong and Beijing [1][3]. - The company plans to enhance its global competitiveness through increased collaboration with international research institutions, which also requires substantial financial support [1][3]. Decision-Making Process - The company's board of directors approved the profit distribution plan with a unanimous vote of 9 in favor and 0 against during the meeting held on March 28, 2025 [4]. - The supervisory board also approved the distribution plan with a vote of 3 in favor and 0 against, pending approval from the annual shareholders' meeting [5].